Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Paragraph: Mustapha Redouane happily accepted the arrangement. He knew his mother's idea would silence the school's worries about his condition, a rare genetic disorder called xeroderma pigmentosum, or XP, which can make sun rays and other sources of ultraviolet light extremely damaging to the skin and eyes. The disorder is more common in North Africa than much of the world. "I hate the sun anyways. It gives me blisters," he said, sitting on his mother's lap, his face covered with the dark brown freckles that the school director considered a distraction to other students. Now 8, Mustapha has already had 11 operations to remove cancerous growths on his skin. His family is among thousands around the world struggling with XP, and increasingly sharing advice and seeking new treatments. In Morocco, families are also fighting for recognition, government help and the simple right to go to school. The disorder affects about 1 in 10,000 people in North Africa more than 10 times the rate in Europe and about 100 times the rate in the United States, according to Dr. Kenneth Kraemer, who researches XP at the U.S. National Institutes of Health. Because the disorder is inherited, XP is more common in populations where marriage between relatives is high, Kraemer said. Affected children inherit two copies of a mutated gene, one from each parent. A 2016 Moroccan government study estimates about 15% of marriages are between family members. Living in a country where the sun shines year-round makes them more susceptible to skin cancers that can be caused by the disorder, said Fatima El Fatouikai, pediatric dermatology specialist at the Ibn Rochd University Hospital in Casablanca. Without protection, few XP patients in Morocco live beyond their teenage years, El Fatouikai said. It is particularly challenging in developing countries, where an awareness of the disorder and access to treatments are scarce, and in poor, rural communities where people spend more time outside. Outside of El Fatoikai's office, families coming from all around Morocco sit in a waiting room eager for their names to be called. There is a rumor about a new XP treatment. The truth is, she says, "We only have prevention as a possible treatment. These children ... have to avoid even minimum sun exposure." The main prevention measures: avoiding the sun and wearing protective clothing, face shields and sunscreen. Fatimazehra Belloucy, 25, has dealt with skin cancer and other problems because of XP. "If only people made it easier. Their words hurt. I feel entirely alienated," she said, describing how she faces scared looks and hateful comments as she passes by. Her family limits interactions with her, fearful that the disease is contagious. "No one would take care of me, so I had to do it myself," said Belloucy, who received her high school diploma and is now enrolled in university. She hopes to land work helping with the disease. Most Moroccan children with XP don't continue their education. While U.S. schools install window filters for XP pupils and otherwise adapt to their needs, such accommodations are rare in Morocco. "It hurts me that I have to see little kids suffer because of lack of awareness," says Habib El Ghazaoui, who quit his veterinary job and made it his life's mission to raise awareness and help children with XP after learning that his daughter Fatimazehra had the disorder. His daughter, now a young adult raising awareness on social media, has had 50 operations for cancerous growths on her tongue, eyelids and elsewhere. She stays indoors and mostly sleeps during the day but, as the sun sets, she goes to parks and cafes, determined to lead a normal life. Ghazaoui leads the Association for Solidarity with Children of the Moon from his house in the town of Mohammedia. He juggles his time between visiting families, distributing donations of creams and masks, providing the Casablanca hospital with data and pressuring the government to take action. XP support groups are increasingly sharing advice online. They held an exceptional meeting in London last year to share "hundreds of practical hints" about hoods, window protections or meters to measure light and even a French-designed face shield with a fan in it, said NIH researcher Deborah Tamura. The donations from Ghazaoui's group reach families like those of Said El Mohamadi, a tailor in the city of Sale, whose 6-year-old daughter has the condition. His family is still debating the topic of school. "She's sad, but I can't risk taking her to school where there isn't any kind of protection," he said. "But she needs an education," her mother Maria El Maroufi pleads. ___ Nadine Achoui-Lesage and Mosa'ab Elshamy in Casablanca and Mohammedia contributed. Claim: When light is lethal: Moroccans struggle with skin disorder.
Determined for her 7-year-old son to attend school despite a life-threatening sensitivity to sunlight, Nadia El Rami stuck a deal with the school's director: Mustapha would be allowed in the classroom, but only if he studies inside a cardboard box.

Paragraph: Researchers around the world are working to develop potential treatments or vaccines against the respiratory disease that has killed nearly 47,000 people and infected almost a million in just a few months. A team at the University of Pittsburgh School of Medicine in the United States said they were able to move quickly in developing a potential COVID-19 vaccine after working on other coronaviruses that cause Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). "These two viruses, which are closely related to SARS-CoV-2 (the new coronavirus causing the COVID-19 pandemic), teach us that a particular protein, called a spike protein, is important for inducing immunity against the virus," said Andrea Gambotto, an associate professor at Pittsburgh. "We knew exactly where to fight this new virus." When tested in mice, the prototype vaccine - which the researchers have called PittCoVacc - generated what they described as "a surge of antibodies" against the new coronavirus within two weeks. The Pittsburgh researchers cautioned that because the animals have not been tracked for very long as yet, it is too early to say whether and for how long the immune response against COVID-19 lasts. But they said that in comparable tests in mice with their MERS experimental vaccine, a sufficient level of antibodies was produced to neutralize the virus for at least a year. So far, the antibody levels of the SARS-CoV-2 vaccinated animals seem to be following the same trend, they said in peer-reviewed study in the journal EBioMedicine. The team said they hope to start testing the vaccine candidate on people in clinical trials in the next few months. The potential vaccine uses a needle patch design, called a microneedle array, to increase its potential potency. This array is a fingertip-sized patch of 400 tiny needles made out of sugar and the spike protein, Gambotto explained. It is designed to deliver the spike protein pieces into the skin, where the immune reaction is strongest. Claim: Potential COVID-19 vaccine shows promise in mouse study.
Initial tests in mice of a potential COVID-19 vaccine delivered via a fingertip-sized patch have shown it can induce an immune response against the new coronavirus at levels that might prevent infection, U.S. scientists said on Thursday.

Paragraph: Calquence (acalabrutinib) belongs to a class of drugs called Bruton's tyrosine kinase (BTK) inhibitors which can suppress autoimmune diseases. The drug, which is currently used to treat certain types of blood cancers, has already been approved for the treatment of adult patients with chronic lymphocytic leukaemia in the U.S. and several other countries. Calquence competes with AbbVie Inc (ABBV.N) and Johnson & Johnson's (JNJ.N) established treatment Imbruvica as a treatment for chronic lymphocytic leukemia, one of the most common types of leukemia in adults. The British drugmaker's shares rose as much as 7.3% to 7642 pence by 0855 BST. AstraZeneca's announcement comes as drugmakers are having to pause clinical trials for other disease areas as they focus on testing potential treatments for the fast-spreading coronavirus. Patients with severe symptoms including pneumonia are believed to suffer from an over reaction of the immune system known as cytokine storm and AstraZeneca aims to test whether Calquence, which suppresses certain elements of the immune system, can help control this immune response. "Given the well documented role of the protein BTK in regulating inflammation, it is possible that inhibiting BTK with acalabrutinib could provide clinical benefit in patients with advanced COVID-19 lung disease," said Louis Staudt, chief of the lymphoid malignancies branch at the National Cancer Institute. The trial will evaluate the effectiveness and safety of adding the drug to best supportive care to reduce mortality and the need for assisted ventilation in patients with life-threatening COVID-19 symptoms, the drugmaker said. It is expected to open for enrolment in the coming days in the U.S. and several countries in Europe, AstraZeneca said. Earlier this month, AstraZeneca and its domestic rival GlaxoSmithKline PLC (GSK.L) agreed to set up a testing laboratory to aid in COVID-19 testing with Cambridge University. Claim: AstraZeneca to test impact of cancer drug Calquence on coronavirus patients.
AstraZeneca Plc (AZN.L) said on Tuesday it would start a clinical trial of its cancer drug Calquence to assess its potential to control the exaggerated immune system response associated with COVID-19 infection in severely ill patients.